Flagship Pioneering, LLC Long-Term Concentrated

Location: Cambridge, MA

CIK: 0001400240 · Show all filings

Period: Q2 2020 (← Previous) (Next →)

Filing Date: Aug 13, 2020

Total Value: $3.442B (100.0% shares, 0.0% debt)

Holdings (8)

MRNA Moderna Inc 74.4%

Value $2.56B Shares 39,871,524 Est. Cost $16.43 Unrealized +233.2%

— Rubius Therapeutics Inc 6.7%

Value $229M Shares 38,296,526 Est. Cost $24.00 Unrealized —

DNLI Denali Therapeutics Inc 5.6%

Value $193M Shares 7,980,263 Est. Cost $17.97 Unrealized +30.8%

KLDO Kaleido Biosciences Inc 4.2%

Value $144M Shares 19,360,710 Est. Cost $13.03 Unrealized -48.6%

— Evelo Biosciences Inc 3.3%

Value $112M Shares 22,900,069 Est. Cost $10.39 Unrealized —

— Seres Therapeutics Inc 3.0%

Value $103M Shares 21,571,764 Est. Cost $8.55 Unrealized —

— Axcella Health Inc 2.0%

Value $69.39M Shares 12,548,414 Est. Cost $8.17 Unrealized —

— Syros Pharmaceuticals Inc 0.9%

Value $31.32M Shares 2,938,494 Est. Cost $13.87 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
MRNA	Moderna Inc	39,871,524	$2.56B	74.4%	$16.43	+233.2%	COM	60770K107
—	Rubius Therapeutics Inc	38,296,526	$229M	6.7%	$24.00	—	COM	78116T103
DNLI	Denali Therapeutics Inc	7,980,263	$193M	5.6%	$17.97	+30.8%	COM	24823R105
KLDO	Kaleido Biosciences Inc	19,360,710	$144M	4.2%	$13.03	-48.6%	COM	483347100
—	Evelo Biosciences Inc	22,900,069	$112M	3.3%	$10.39	—	COM	299734103
—	Seres Therapeutics Inc	21,571,764	$103M	3.0%	$8.55	—	COM	81750R102
—	Axcella Health Inc	12,548,414	$69.39M	2.0%	$8.17	—	COM	05454B105
—	Syros Pharmaceuticals Inc	2,938,494	$31.32M	0.9%	$13.87	—	COM	87184Q107